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with the non-AC group, AR-AUC was significantly decreased 
in the AC, warfarin, dabigatran and apixaban groups. Only 
the rivaroxaban group did not show a significant decrease in 
AR-AUC. NOACs showed a significant decrease in PL-AUC 
compared with the non-AC group. In conclusion, T-TAS® 
was a useful tool for evaluating anticoagulation activity. 
NOACs was significantly effective as an antiplatelet agent. 
BP control should be a higher priority than the selection of an 
anticoagulant drug, especially NOACs.
Keywords Microchip flow-chamber system · Blood 
pressure · Warfarin · Dabigatran
Introduction
Non-vitamin K antagonist oral anticoagulants (NOACs) are 
frequently used to prevent stroke in patients with atrial fibril-
lation (Af) [1, 2]. The RE-LY study demonstrated that dabi-
gatran was both safe and effective relative to warfarin for 
stroke prevention in nonvalvular Af [3]. The ROCKET AF and 
J-ROCKET AF, ARISTOLE and ENGAGE AF TIMI48 stud-
ies and recent meta-analyses similarly demonstrated that other 
NOACs are also safe and effective [4–8]. Compared to warfa-
rin, the use of NOACs does not require frequent blood sam-
pling for monitoring or dietary restrictions. However, there 
is currently no tool for evaluating the anticoagulant effects 
of NOACs under clinical conditions [9, 10]. For patients 
with active bleeding associated with a high concentration of 
NOACs, a strategy for assessing the extent of anticoagulation 
is needed in the clinical field [10–13]. On the other hand, the 
PROGRESS study showed that blood pressure (BP)-lowering 
is also important for the prevention of active bleeding [14].
Recently, the Total Thrombus-formation Analysis Sys-
tem (T-TAS®) [15–17] was developed by Fujimori Kogyo, 
Abstract The Total Thrombus-formation Analysis System 
(T-TAS®) is a novel automated microchip flow-chamber 
system for the quantitative evaluation of thrombus forma-
tion under blood flow conditions. T-TAS® uses two types of 
microchip to evaluate thrombus formation: the AR-chip quan-
tifies white thrombus formation and the PL-chip quantifies 
platelet thrombus formation. We assessed the antithrombotic 
abilities of various non-vitamin K antagonist oral anticoagu-
lants (NOACs) using T-TAS®. One hundred and three con-
secutive patients who were hospitalized with cardiovascular 
diseases were enrolled. We divided the patients into 2 groups; 
a control group that did not receive an anticoagulant (non-AC 
group) and an anticoagulant group (AC group). The AC group 
was further divided into warfarin, dabigatran, rivaroxaban and 
apixaban groups. We performed common coagulation tests 
and evaluated the area under the flow pressure curve (AR-
AUC and PL-AUC) to quantify antithrombotic ability using 
T-TAS® at the trough. There were no significant differences 
in patient characteristics between the non-AC and AC groups. 
Only 55.1 % of patients in the AC group achieved the target 
blood pressure (BP) of less than 130/80 mmHg. Compared 
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Kanagawa, Japan. This system is an automated microchip 
flow chamber system for the quantitative analysis of throm-
bus formation. This new system can evaluate thrombo-
genicity under blood flow conditions, and it is expected that 
the measurement of thrombus formation under flow condi-
tions will more directly reflect thrombotic events. Using the 
T-TAS®, we previously reported the diurnal variation of the 
anticoagulant effect of rivaroxaban [18]. In addition, a pre-
vious study indicated that the values obtained by T-TAS® 
were clinically significant [19]. T-TAS® was potentially 
useful for predicting bleeding events in atrial fibrillation 
patients undergoing catheter ablation. In this study, we 
used T-TAS® to assess the antithrombotic abilities of vari-
ous NOACs.
Methods
Blood samples
We enrolled 103 consecutive patients [male (n = 61, 59 %), 
female (n = 42, 41 %), average age 68.0 ± 12.7 years] who 
were hospitalized with cardiovascular disease (CVD). All 
patients did not receive any antiplatelet drugs that could 
have affected platelet function except for warfarin and 
NOACs. Seventy-eight of these 103 patients had received 
an anticoagulant (AC group), and the others did not 
(n = 25, non-AC group). The patients in the non-AC group 
had arrhythmia (42 %), heart failure (28 %), coronary 
artery disease (16 %), and so on. On the other hand, the 
AC group consisted entirely of Af patients, and the NOAC 
group consisted of patients with non-valvular Af. Blood 
samples were collected at 6–7 am. The patients received 
NOACs once a day (at 7–8 am) or twice a day (at 7–8 am 
and 6–7 pm). We evaluated the results of common coagula-
tion tests such as the prothrombin time-international nor-
malized ratio (PT-INR), activated partial thromboplastin 
time (APTT) and complete blood count. This study was 
conducted in accordance with the Declaration of Hel-
sinki, approved by the Independent Review Board (IRB) of 
Fukuoka University Hospital (Fukuoka University Hospital 
IRB: #14-4-04) and registered under UMIN000017228. All 
subjects gave their written informed consent to participate.
Evaluation of thrombus formation under flow 
conditions
T-TAS® uses two types of single-use microchip, PL-chip 
and AR-chip, as described previously [15–17, 20]. The PL-
chip contains 25 capillary channels (40 μm wide × 40 μm 
deep) coated with type I collagen, and is used for the 
quantitative evaluation of platelet-specific thrombus forma-
tion under arterial flow conditions. The AR-chip contains 
a single capillary channel (300 μm wide × 80 μm deep) 
coated with type I collagen and tissue thromboplastin. 
Thus, T-TAS® can be used for the quantitative evaluation 
of white thrombus formation mediated by the activation of 
both coagulation and platelets.
Samples were collected into plastic tubes containing 
3.2 % sodium citrate, and into hirudin-anticoagulant tubes. 
Blood was used after it was allowed to rest for 1 h from the 
time of collection. For the evaluation of platelet thrombus 
formation, a whole blood sample (330 μl) anticoagulated 
with hirudin was applied to the PL-chip at a flow rate of 
18 μl/min, and the initial wall shear rate was estimated 
to be 2000 s−1 [21]. In the PL-chip, platelets adhere and 
aggregate on the surface of collagen, and capillaries are 
occluded. The thrombus-formation processes are analyzed 
under continuous monitoring of the internal pressure of the 
PL-chip due to this capillary occlusion. The area under the 
flow pressure curve (AUC) was computed to assess plate-
let thrombogenicity inside the microchips. We defined 
PL-AUC as the AUC for the first 10 min for the PL-chip 
tested at a flow rate of 18 μl/min. In addition, for the evalu-
ation of white thrombus formation, a whole blood sample 
(480 μl) with 3.2 % sodium citrate was mixed with CaCl2 
(20 μl) just before measurement. The mixture, which had a 
volume of 480 μl, was applied to the AR-chip at a flow rate 
of 10 μl/min, and the initial wall shear rate was estimated 
to be 600 s−1. We defined AR-AUC as the AUC for the first 
30 min.
Assessment of cardiovascular risk factors
Data on weight, height, serum levels of triglycerides (TG), 
high-density lipoprotein cholesterol (HDL-C), and low-
density lipoprotein cholesterol (LDL-C), total cholesterol 
(TC), estimated glomerular filtration rate (eGFR), fast-
ing blood glucose (FBS) and hemoglobin A1c were col-
lected. The patient characteristics, including the history 
of hypertension (HTN), dyslipidemia (DL), diabetes mel-
litus (DM), chronic kidney disease (CKD), smoking status, 
and medication use, were obtained from medical records. 
Patients who had a current systolic BP (SBP)/diastolic BP 
(DBP) ≥140/90 mmHg or who were receiving antihyper-
tensive therapy were considered to have HTN. Patients 
with low-density lipoprotein cholesterol ≥140 mg/dl and/
or triglycerides ≥150 mg/dl or high-density lipoprotein 
cholesterol ≤40 mg/dl, or who were receiving lipid-lower-
ing therapy were defined as DL. DM was defined using the 
Japanese Diabetes Society criteria. Body mass index was 
calculated as weight (kg)/height (m)2.
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Statistical analysis
A statistical analysis was performed using the Stat View 
statistical software package (Stat View 5; SAS Institute 
Inc., Cary, NC, USA) and the SAS (Statistical Analysis 
System) Software Package (Ver. 9.4, SAS Institute Inc., 
Cary, NC, USA). Data are shown as the mean ± stand-
ard deviation (SD). Categorical and continuous vari-
ables were compared between the groups by a Chi square 
analysis and unpaired test, respectively. Since AR-AUC 
and PL-AUC did not show normal distribution, the data 
was expressed as a median value and interquartile range 
and a Kruskal–Wallis test was performed. The Spearman 
Rank Correlation Coefficient was used to evaluate asso-
ciation between the groups. The Levene’s test and Ansari-
Bradley test for homogeneity of variances were used to 
compare variances for continuous variables between and 
among groups [22, 23]. A value of p < 0.05 was consid-
ered significant.
Results
Patient characteristics in the non‑AC, AC, warfarin, 
dabigatran, rivaroxaban and apixaban groups
The patient characteristics are shown in Table 1. Daily doses 
of dabigatran, rivaroxaban and apixaban were 300 (57 %) and 
220 (47 %) mg/day, 15 (46 %) and 10 (54 %) mg/day, and 10 
(64 %) and 5 (36 %) mg/day, respectively. There were no sig-
nificant differences in patient characteristics, including gen-
der, HTN, DM, and DL except for age and β blocker between 
the non-AC and AC groups. There were also no significant 
differences in patient characteristics among the AC groups.
Table 1  Patient characteristics 
in the non-AC, AC, warfarin, 
dabigatran, rivaroxaban and 
apixaban groups
Values are shown as the mean ± standard deviation (SD). BMI Body mass index, HTN hypertension, SBP 
systolic blood pressure, DBP diastolic BP, DL dyslipidemia, LDL-C low-density lipoprotein cholesterol, 
HDL-C high-DL-C, TG triglyceride, TC total cholesterol, DM diabetes mellitus, FBS fasting blood glu-
cose, CKD chronic kidney disease, eGFR estimated glomerular filtration rate, ARB angiotensin II receptor 
bloker, ACE-I angiotensin converting enzyme inhibitor, CCB calcium channel blocker
* p < 0.05, ** p < 0.01 vs non-AC group
Non-AC group AC group
All Warfarin Dabigatran Rivaroxaban Apixaban
N 25 78 22 13 27 16
Age (years) 65 69* 72 65 67.4 75.1
Male (%) 48 63 59 77** 58 63
BMI (kg/m2) 22.7 23.8 23.2 22.7 25.1 22.7
Smoking (%) 37 38 36 38 43 38
HTN (%) 66 66 64 62 62 75
 SBP (mmHg) 124 ± 22 121 ± 20 121 ± 21 121 ± 19 124 ± 21 121 ± 22
 DBP (mmHg) 74 ± 16 71 ± 12 70 ± 13 73 ± 12 73 ± 13 63 ± 17
DL (%) 40 42 45 38 42 44
 LDL-C (mg/dl) 108 ± 27 90 ± 30 91 ± 27 87 ± 14 102 ± 26 85 ± 48
 HDL-C(mg/dl) 55 ± 14 47 ± 17 46 ± 18 56 ± 17 48 ± 15 44 ± 19
 TG (mg/dl) 119 ± 50 108 ± 54 102 ± 44 92 ± 39 114 ± 64 112 ± 57
 TC (mg/dl) 186 ± 32 166 ± 45 169 ± 49 171 ± 21 169 ± 51 165 ± 61
DM (%) 14 24 23 13 17 46
 FBS (mg/dl) 98 ± 27 108 ± 37 105 ± 33 104 ± 21 100 ± 25 134 ± 65
 Hemoglobin A1c (%) 6 6 6.1 6 5.9 6.2
CKD (%) 26 48 59 38 43 62
 eGFR (ml/min/1.73 m2) 70 ± 20 58 ± 23 48 ± 27* 63 ± 16 67 ± 22 52 ± 18
Medications
 ARB or ACE-I (%) 40 52 55 38 42 75*
 CCB (%) 43 35 36 31 38 25
 β blocker (%) 26 55** 59 46 58 50
 Diuretics (%) 34 47 64 38 35 56
 Statin (%) 34 37 41 38 35 38
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BP levels in patients with anticoagulant therapy are rec-
ommended to be less than 130/80 mmHg [24]. Although the 
average SBP/DBP in all groups was about 120/70 mmHg, 
the percentage (%) of achievement of the target BP in the 
AC, NOACs, warfarin, dabigatran, rivaroxaban and apixa-
ban groups was 55.1 % (n = 43/n = 78), 58.9 % (33/56), 
45.5 % (10/22), 53.8 % (7/13), 55.6 % (15/27) and 68.8 % 
(11/16), respectively.
Efficacy of anticoagulant drugs
The AUC was computed to assess the total thrombogenicity 
inside the microchips. If the thrombus forms in the capil-
laries of a microchip early, the internal pressure should rise 
quickly and the value of the AUC will increase. In contrast, 
when anticoagulant drugs are more effective, the thrombus 
will form more slowly and this value will decrease.
AR-AUC in the non-AC, AC, warfarin, dabigatran, 
rivaroxaban and apixaban groups was 1628 (1373-1748), 
1247 (944-1416), 1207 (735-1356), 1109 (736-1356), 1366 
(1156-1539), and 1172 (1037-1389) arbitrary units (AU), 
respectively (Fig. 1A). Compared with the non-AC group, 
AR-AUC was significantly decreased in the warfarin, dabi-
gatran and apixaban groups. Only the rivaroxaban group 
did not show a significant decrease in AR-AUC. On the 
other hand, PL-AUC in the non-AC, AC, warfarin, dabi-
gatran, rivaroxaban and apixaban groups were 342 (278-
381), 220 (118-324), 227 (153-261), 201 (71-328), 212 
(122-334) and 224 (97-270) AU, respectively (Fig. 1B). All 
AC, warfarin, dabigatran, rivaroxaban and apixaban groups 
showed significant reductions in PL-AUC compared with 
the non-AC group.
We also evaluated the differences in AR-AUC and 
PL-AUC between males and females in the non-AC, AC, 
warfarin, dabigatran, rivaroxaban and apixaban groups 
(Table 2). As a result, there were no significant differences 
between males and females in each group.
Common coagulation tests
PT-INR, APTT, red cell count, hematocrit and platelets 
(Plt) are shown in Table 3. The dabigatran and warfarin 
groups showed significantly higher levels of APTT than the 
non-AC group. PT-INR in the warfarin group was a good 
control, and the value was 1.8 ± 0.3. In addition, PT-INR 
in the warfarin group was significantly higher than that in 
the non-AC group. Plt in the AC, dabigatran and apixaban 
groups were significantly lower than that in the non-AC 
group.
Fig. 1  AR-AUC (A) and PL-AUC (B) in the non-AC, AC, warfarin, 
dabigatran, rivaroxaban and apixaban groups. *p < 0.05, **p < 0.01 
vs non-AC group. AU arbitrary unit
Table 2  AR-AUC and PL-AUC 
between males and females 
in the non-AC, AC, warfarin, 
dabigatran, rivaroxaban and 
apixaban groups
The data was expressed as a median value and interquartile range
AU arbitrary unit
AR-AUC (AU) PL-AUC (AU)
Males Females p value Males Females p value
Non-AC 1578 (1374–1707) 1650 (1277–1768) 0.681 306 (264–383) 348 (300–378) 0.504
AC 1270 (942–1440) 1221 (949–1398) 0.785 201 (76–334) 231 (174–270) 0.694
Warfarin 925 (566–1317) 1232 (977–1357) 0.410 176 (61–252) 240 (225–265) 0.148
Dabigatran 1160 (440–1525) 1109 (1107–1101) 0.818 201 (107–332) 165 (85–245) 0.606
Rivaroxaban 1367 (1213–1512) 1295 (1040–1527) 0.799 235 (134–351) 212 (82–277) 0.413
Apixaban 1194 (1140–1379) 1066 (970–1323) 0.456 230 (9–273) 234 (185–263) 0.776
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Associations between AUC and PT‑INR or APTT in all 
patients and the AC group
We also evaluated the associations between AR-AUC or 
PL-AUC and PT-INR or APTT in all patients (Fig. 2) 
and the AC group (Fig. 3). As a result, AR-AUC was 
significantly, albeit weakly, and negatively correlated 
with PT-INR and APTT (Fig. 2). In addition, PL-AUC 
in all patients was not correlated with PT-INR or APTT 
(Fig. 2). In the AC group, there were no associations 
between AR-AUC or PL-AUC and PT-INR or APTT 
(Fig. 3).
Table 3  Common coagulation 
test in the non-AC, AC, 
warfarin, dabigatran, 
rivaroxaban and apixaban 
groups
APTT activated partial thromboplastin time, PT-INR prothrombin time-international normalized ratio, RBC 
red cell counts, Hct hematocrit, Plt plates
*p < 0.05, **p < 0.01 vs non-AC group
Non-AC group AC group
All Warfarin Dabigatran Rivaroxaban Apixaban
APTT (S) 29 ± 3 36 ± 8 38 ± 5** 38 ± 4** 34 ± 10 32 ± 5
PT-INR 1.1 ± 0.1 1.3 ± 0.3 1.8 ± 0.3** 1.2 ± 0.1 1.2 ± 0.1 1.1 ± 0.1
RBC (104/μl) 433 ± 61 418 ± 77 382 ± 107 457 ± 84 443 ± 43 401 ± 61
Hct (%) 41 ± 5 40 ± 5 38 ± 7 43 ± 6 41 ± 4 38 ± 5
Plt (104/μl) 25 ± 5 18 ± 6* 18 ± 6 17 ± 8* 21 ± 7 18 ± 5*
Fig. 2  Associations between 
AR-AUC or PL-AUC and PT-
INR or APTT in all patients
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Discussion
In this study, we found that only 55.1 % of patients with 
anticoagulant therapy achieved a target BP of less than 
130/80 mmHg. In addition, AR-AUC in the AC, warfa-
rin, dabigatran and apixaban groups were significantly 
decreased compared with that in the non-AC group. Only 
the rivaroxaban group did not show a significant decrease 
in AR-AUC. Finally, NOACs showed significant decreases 
in PL-AUC.
AR-AUC in the AC group was significantly lower than 
that in the non-AC group, which confirmed that this sys-
tem can precisely monitor anticoagulant effects in humans. 
Although we did not assess the time course of AR-AUC 
throughout the day, we observed a significant difference 
between the AC and non-AC groups at the trough. We also 
evaluated AR-AUC and PL-AUC in patients who took aspi-
rin or aspirin plus clopidogrel (dual anti platelet therapy; 
DAPT). The results of AR-AUC and PL-AUC in the non-
AC, aspirin and DAPT groups are shown in Supplementary 
Figure 1. Although there were no differences in AR-AUC 
among the non-AC, aspirin and DAPT groups, PL-AUC 
in the aspirin group was significantly lower than that in 
the non-AC group, and that in the DAPT group was sig-
nificantly lower than that in the aspirin group. As shown 
in Fig. 3, AR-AUC in the AC group was not significantly 
associated with PT-INR and APTT. In addition, PL-AUC 
did not show any correlations with PT-INR and APTT, 
which indicates that T-TAS® monitoring can assess antico-
agulant and antiplatelet effects independent of PT-INR and 
APTT for assessing these effects. Thus, T-TAS® is more 
useful for monitoring these effects in a clinical setting.
NOACs were associated with a significant decrease in 
PL-AUC compared with the control group. Interestingly, the 
platelet thrombus-formation process (PL-AUC) in patients 
with 100 mg/day aspirin [189 (63–223) AU; Supplemen-
tary Figure 1] was comparable to those in the dabigatran, 
apixaban and rivaroxaban groups [201 (71–328) AU, 231 
(97–270) AU and 214 (122–334) AU, respectively; Fig. 1B]. 
Thus, all NOACs may have both anticoagulant and anti-
platelet actions. Thrombin has many physiological effects, 
including the activation of platelets [25, 26]. Dabigatran 
Fig. 3  Associations between 
AR-AUC or PL-AUC and PT-
INR or APTT in the AC group
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specifically blocks thrombin, and reduces the rate of throm-
bin production [27, 28]. Apixaban and rivaroxaban specifi-
cally block the function of factor Xa. Although they decrease 
the total amount of thrombin and reduce the rate of thrombin 
production, these effects may be weak [29]. Thrombin is the 
most powerful platelet activator in vivo, and the inhibition of 
thrombin production by NOAC is correlated with antiplatelet 
action. Although the antiplatelet action of a direct thrombin 
inhibitor is moderate, and that of a direct factor Xa inhibi-
tor is weak [30], antiplatelet actions of 2 kinds of inhibitors 
were similar according to our data as assessed by T-TAS®. 
NOAC in addition to dual antiplatelet therapy was associ-
ated with a dose-dependent increase in bleeding events [31]. 
Bleeding events are the greatest problem for patients with 
Af who have undergone percutaneous coronary intervention 
and received triple antithrombotic therapy. If the antiplatelet 
action of NOAC including dabigatran is the same as those 
of antiplatelet drug, as we mentioned, it may be possible to 
treat these patients with NOAC and single antiplatelet drug.
As expected, AR-AUC in the AC, warfarin, dabigatran and 
apixaban groups were significantly decreased compared with 
that in the non-AC group. Only the rivaroxaban group did not 
show a significant difference in AR-AUC compared with the 
non-AC group at the trough. We considered that this is not 
because the anticoagulant efficacy of rivaroxaban is insuffi-
cient, but rather because rivaroxaban is taken once a day and 
the blood samples were obtained at the time of the trough.
BP control is important for patients who are receiving 
anticoagulant therapy to prevent active bleeding. On the 
other hand, the percentage of patients who achieved BP 
control in the AC group was only 55.1 % in this study. 
Therefore, for the prevention of active bleeding, BP control 
should be more important than the selection of anticoagu-
lant drug, especially NOACs.
This study has several limitations. First, the study was 
cross-sectional and included a relatively small number 
of patients. Second, the measurements in the thrombus-
formation analysis were performed at the trough. Throm-
bus-formation should also be assessed at the peak of an 
effect. Third, many of the patients had HTN, DM or DL, 
which may have influenced the measurements, although 
the patients did not receive any medications that should 
have affected thrombus-formation except for warfarin 
and NOACs. Fourth, Virchow’s triad refers to three fac-
tors related to thrombosis. This study focused on only one 
member of the triad. Further studies will be needed to clar-
ify the effects of these limitations.
Conclusion
In this study, we evaluated the antithrombotic abilities of 
warfarin and NOACs by using T-TAS®. T-TAS® was a 
useful tool for evaluating anticoagulant action. In the evalu-
ation of antiplatelet action, NOACs showed significant anti-
platelet efficacy. BP control should be more important than 
the selection of anticoagulant drug, especially for NOACs.
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